Visal Numrungroad

The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design

Sradha Kotwal, Vlado Perkovic, Meg Jardine, Dana Kim et autres

au, nl, gb, us, cn, jp, in, es (code pays fourni par la source)

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Rajiv Agarwal, Wanzhu Tu, Alfredo E. Farjat, Youssef M.K. Farag et autres

us, gb, de, es, dk, gr, pl (code pays fourni par la source)

Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888–897

Peter Rossing, Ellen Burgess, Rajiv Agarwal, Stefan D. Anker et autres

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt et autres

dk, de, gr, us, es, gb (code pays fourni par la source)

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

Ellen Burgess, Rajiv Agarwal, Stefan D. Anker, Gerasimos Filippatos et autres

dk, ca, us, de, gr, es, be, au, il (code pays fourni par la source)

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

Hiddo J.L. Heerspink, David Z.I. Cherney, Douwe Postmus, Bergur V. Stefánsson et autres

nl, au, ca, se, us, gb, mx, dk (code pays fourni par la source)

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

Hiddo J.L. Heerspink, C. David Sjöström, Niels Jongs, Glenn M. Chertow et autres

nl, au, se, us, cn, gb, dk, pl (code pays fourni par la source)